y 

ValiRx Plc

("ValiRx" or "the Company")

CLINICAL TRIAL UPDATE

'Positive VAL201 Results'

London, UK., 11 January 2017: ValiRx Plc (AIM: VAL), a clinical stage biotechnology company, announces positive results in its VAL201 personalised Phase l/II prostate cancer study with accumulation of safety and tolerability data there is also evidence of disease stabilisation on CT imaging and reduction in PSA progression in the majority of patients.  The Company has extended the study to more clinical sites involving more patients in order to build on these initial positive findings.

VAL201 is unlike current therapies for advanced prostate cancer, which often include androgen deprivation.  VAL201 is intended to target a specific pathway from the androgen receptor, treating the cancer without suppressing sexual and other functions and without many other debilitating side effects many therapies have.

Building on these positive results, ValiRx is adding additional clinical sites to participate in the dose-escalating, therapeutically relevant phase of the trial to arrive at the maximum tolerated dose.  This can be taken forward by the Company or a partner into subsequent, larger, outcomes-oriented clinical trials to establish its effect on overall survival and health-related quality of life in patients with prostate cancer.

Dr Satu Vainikka, CEO of ValiRx, commented: "VAL201 has demonstrated disease stabilisation, with a lower dose than was predicted by our preclinical evaluations.  We anticipate that by increasing the dosage we will show a high level of efficacy without compromising the safety and tolerability shown to date to meet the needs of those patients currently under-served by current therapies. ValiRx is entering a very exciting phase, which should result in the crystallisation of substantial value".

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

*** ENDS ***

For more information, please contact:

Notes for Editors

ValiRx Plc

ValiRx is a biotechnology oncology focused company specialising in developing novel treatments for cancer and associated biomarkers.  It aims to make a significant contribution in "precision" medicine and science, namely to engineer a breakthrough into human health and well-being, through the early detection of cancer and its therapeutic intervention.

The Company's business model focuses on out-licensing therapeutic candidates early in the development process. By aiming for early-stage value creation, the company reduces risk considerably while increasing the potential for realising value. The group is already in licensing discussions with major players in the oncology field.

ValiRx's two classes of drugs in development, which each have the potential for meeting hitherto unmet medical needs by existing methods, have worldwide patent filings and agreed commercial rights.   They originate or derive from Word class institutions, such as Cancer Research UK and Imperial College. 

Until recently, cancer treatments relied on non-specific agents, such as chemotherapy.  With the development of target-based agents, primed to attack cancer cells only, less toxic and more effective treatments are now possible. New drugs in this group-such as those in ValiRx's pipeline-promise to greatly improve outcomes for cancer patients.

The Company listed on the Alternative Investment Market ("AIM") of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.